Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.
Many patients with secondary progressive multiple sclerosis (SPMS) are actually being misclassified and treated as if they have relapsing-remitting MS (RRMS), which can have an impact on research, treatment, and health care planning, said Jan Hillert, MD, PhD, professor and senior physician at Karolinska Institutet.
Why do you think misclassification of relapsing-remitting MS as secondary progressive MS occurs? And how can that misclassification be avoided?
So, the background is that we've seen that the proportion of people supposedly having SPMS varies between different data sources, whether different materials from different countries different MS registries. And of course, we wonder why that is. Is that because patients with SPMS are neglected by MS care? The reason [is] because they are, they may actually be, misclassified.
And therefore, now that we are starting to get to treatments that are specifically approved for SPMS it becomes more important for us to know: what is the proportion these days of SPMS? And I mean, this is important for us, as physicians to plan our treatments to plan our health care, plan economically, possibly, depending on your system. So, it became really important to know.
And that's why we thought that an objective algorithm that would designate patients into RRMS or SPMS would be a useful thing, at least in research, and also in health care planning, Potentially, also in the clinical situation, depending on how you can use it.
What is the algorithm and how can providers and clinicians use it to make sure that they're not misclassifying patients with MS?
So, the idea though, and there have been several different ways of trying to find the best way to assign RRMS and SPMS. But a general problem with those is that they require quite a bit of information, most typically several points of EDSS [Expanded Disability Status Scale] measurement. Whereas in practical life, as well as in many databases, you have the scarcity of EDSS points.
So, we wanted to set up something simple that required just age and 1 EDSS. And if we could find out an algorithm that could actually do a good job based only on those 2 variables, then that would be great. And that's what we set out to do.
And that, in the end, appeared to be possible. We applied some machine learning techniques to categorize patients into age groups and EDSS groups. And then we came up with the best model, we prune the model to bring it down to something more practical, and then that ended up in this algorithm that we now have as this decision tree classification. And it's not yet published, I should say it's submitted, like to be published pretty soon.
Specialty Pharmacists at the Forefront: Elevating Care for Rare Diseases
May 1st 2024In the US, a disease is considered rare when it affects fewer than 200,000 persons, or 1 in every 1500 individuals, with an estimated total of 25 to 30 million Americans overall living with a rare disease at any given time.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Latest Advances and Updates of Treatment in the Real World at AUA
May 1st 2024The annual meeting of the American Urological Association (AUA) not only presents the newest therapies coming out but showcases the latest in how treatments are being used in the real world, said Stephen Freedland, MD, of Cedars Sinai.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
AUA to Focus on Inclusive Care, Robotic Surgeries, and Future of Urology at 2024 Annual Meeting
May 1st 2024The American Urological Association (AUA) 2024 Annual Meeting will highlight the latest innovations and future trends in urology, featuring dynamic plenary sessions, educational opportunities for providers, and discussions on cutting-edge treatments and global health initiatives.
Read More
OptumRx’s Jon Mahrt Discusses “Irresponsible” Drug Pricing for Products With Multiple Indications
April 30th 2024When the same product comes to market with additional indications, irrational pricing decisions result in ever increasing prices instead of volume translating to lower costs, said Jon Mahrt, MBA, of OptumRX.
Read More